Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker BSX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clini… NCT07209852 · Bradycardia, Atrioventricular Block Pacemaker lead | BSX Boston Scientific Corporation | — | Active, not recruiting | 141 | Aug 31, 2029 | Registry ↗ |
| Nov 13, 2026 | Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain NCT06827262 · Chronic Low-back Pain, Vertebrogenic Pain Syndrome Intracept™ Intraosseous Nerve Ablation | BSX Boston Scientific Corporation | — | Recruiting | 1,500 | Jul 2034 | Registry ↗ |
| Nov 13, 2026 | Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET) NCT04032470 · Essential Tremor Deep Brain Stimulation Systems (DBS) | BSX Boston Scientific Corporation | — | Recruiting | 500 | Dec 2039 | Registry ↗ |
| Nov 13, 2026 | RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness o… NCT01719055 · Pain neurostimulation system | BSX Boston Scientific Corporation | — | Recruiting | 4,800 | May 2035 | Registry ↗ |
| Nov 12, 2026 | Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control NCT07190807 · Chronic Pain, Intractable Pain Boston Scientific WaveWriter Alpha™ SCS Systems | BSX Boston Scientific Corporation | Not applicable | Recruiting | 70 | Nov 2027 | Registry ↗ |
| Nov 12, 2026 | Stone and Laser Therapies Post-Market Study (SALT) NCT06982235 · Benign Prostate Hypertrophy(BPH), Renal Calculi Ureteroscope system, Laser system | BSX Boston Scientific Corporation | — | Active, not recruiting | 238 | Feb 2029 | Registry ↗ |
| Nov 12, 2026 | Hot AXIOS™ for Bile Duct Drainage in Malignant Stenosis NCT06750146 · Malignant Biliary Stenosis Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System | BSX Boston Scientific Corporation | Not applicable | Suspended | 162 | May 2027 | Registry ↗ |
| Nov 12, 2026 | SIMPLAAFY Clinical Trial NCT06521463 · Atrial Fibrillation, Stroke WATCHMAN FLX Pro LAAC Device | BSX Boston Scientific Corporation | Not applicable | Active, not recruiting | 1,857 | Jul 7, 2026 | Registry ↗ |
| Nov 12, 2026 | SpaceIT Hydrogel System for Perirectal Spacing NCT06451614 · Prostate Cancer SpaceIT Hydrogel System, Commercially available Boston Scie… | BSX Boston Scientific Corporation | Not applicable | Active, not recruiting | 230 | Sep 30, 2026 | Registry ↗ |
| Nov 12, 2026 | Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer NCT04905069 · Prostate Cancer SpaceOAR Vue System | BSX Boston Scientific Corporation | Not applicable | Active, not recruiting | 500 | Dec 2027 | Registry ↗ |
| Nov 12, 2026 | REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men NCT04838769 · Benign Prostatic Hyperplasia (BPH) REZŪM, alpha blocker and 5-alpha reductase inhibitor | BSX Boston Scientific Corporation | Not applicable | Active, not recruiting | 155 | Dec 11, 2025 | Registry ↗ |
| Nov 12, 2026 | Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Ant… NCT04798768 · Tachycardia, Ventricular, Arrhythmia, Ventricular mCRM Therapy System | BSX Boston Scientific Corporation | Not applicable | Active, not recruiting | 297 | May 6, 2024 | Registry ↗ |
| Nov 12, 2026 | IT Matters: The Erectile Restoration Registry NCT04200937 · Erectile Dysfunction Tactra Malleable, Spectra™ Concealable Penile Prothesis | BSX Boston Scientific Corporation | — | Enrolling by invitation | 450 | Jan 2031 | Registry ↗ |
| Nov 12, 2026 | A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE) NCT04192591 · Lumbar Spinal Stenosis Superion™ IDS device | BSX Boston Scientific Corporation | Not applicable | Active, not recruiting | 166 | Feb 2038 | Registry ↗ |
| Nov 12, 2026 | Intra-operative Pancreatoscopy in Patients With IPMN NCT03729453 · Intraductal Papillary Mucinous Neoplasm SpyGlass | BSX Boston Scientific Corporation | — | Active, not recruiting | 100 | Aug 11, 2022 | Registry ↗ |
| Nov 12, 2026 | Deep Brain Stimulation (DBS) Retrospective Outcomes Study NCT03664609 · Parkinson Disease, Essential Tremor Deep Brain Stimulation | BSX Boston Scientific Corporation | — | Recruiting | 5,000 | Dec 2028 | Registry ↗ |
| Nov 12, 2026 | Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry NCT02071134 · Parkinson's Disease Deep Brain Stimulation (DBS) | BSX Boston Scientific Corporation | — | Recruiting | 1,500 | Dec 2038 | Registry ↗ |
| Nov 12, 2026 | Patient Retrospective Outcomes (PRO) NCT01550575 · Chronic Pain Non Boston Scientific Systems, Boston Scientific Systems | BSX Boston Scientific Corporation | — | Recruiting | 15,000 | Dec 2030 | Registry ↗ |
| Nov 9, 2026 | The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Us… NCT07925359 · Atrial Fibrillation (AF), Paroxysmal AF Ablation Treatment with FARAPULSE™ Pulsed Field Ablation (P… | BSX Boston Scientific Corporation | Not applicable | Not yet recruiting | 200 | Oct 2027 | Registry ↗ |
| Nov 6, 2026 | Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D) NCT07639684 · Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30) ESG with OverStitch | BSX Boston Scientific Corporation | Not applicable | Not yet recruiting | 50 | Jul 2029 | Registry ↗ |
| Nov 6, 2026 | Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area NCT07035431 · Anastomotic Leaks, Hartmanns Stump Leakage Endo-SPONGE | BSX Boston Scientific Corporation | Not applicable | Recruiting | 66 | Dec 2028 | Registry ↗ |
| Nov 6, 2026 | Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia NCT06686485 · Concomitant Procedures, Atrial Fibrillation FARAPULSE™ PFA system and WATCHMAN LAAC Delivery Systems | BSX Boston Scientific Corporation | — | Active, not recruiting | 433 | Oct 31, 2026 | Registry ↗ |
| Nov 4, 2026 | Safety and Effectiveness of Orbera365™ Intragastric Balloon System NCT07062094 · Obesity Intragastric Balloon | BSX Boston Scientific Corporation | — | Recruiting | 200 | Apr 7, 2028 | Registry ↗ |
| Nov 4, 2026 | AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE NCT06174805 · Gastric Outlet Obstruction AXIOS(TM) Stent and Electrocautery Enhanced Delivery System | BSX Boston Scientific Corporation | Not applicable | Suspended | 67 | Sep 2027 | Registry ↗ |
| Nov 3, 2026 | Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchroniz… NCT07069738 · Heart Failure - NYHA II - IV CRT-D with a Quadripolar LV lead, CRT-D with INGEVITY+ pace… | BSX Boston Scientific Corporation | Not applicable | Recruiting | 850 | Nov 2029 | Registry ↗ |
| Nov 2, 2026 | A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of S… NCT06492174 · In-Stent Restenosis AGENT DCB 40 mm | BSX Boston Scientific Corporation | Phase 3 | Active, not recruiting | 20 | Dec 19, 2025 | Registry ↗ |
| Nov 2, 2026 | BoStOn SCientific Rhythm MAnagemenT REgiStry NCT04823663 · Cardiac Disease Implant, Electrophysiologic procedure | BSX Boston Scientific Corporation | — | Recruiting | 12,500 | Dec 31, 2030 | Registry ↗ |
| Nov 2, 2026 | A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of S… NCT04647253 · In-Stent Restenosis AGENT DCB, PTCA balloon catheter | BSX Boston Scientific Corporation | Phase 3 | Active, not recruiting | 600 | Oct 2, 2023 | Registry ↗ |
| Oct 30, 2026 | A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning. NCT07669727 · Hepatocellular Carcinoma (HCC) TheraSphere | BSX Boston Scientific Corporation | — | Not yet recruiting | 140 | May 2028 | Registry ↗ |
| Oct 30, 2026 | A Prospective, Multicenter, Single Arm Registry of ENROUTE NPS in Conjunction With Carotid WALLSTEN… NCT07458243 · Carotid Artery Stenosis transcarotid artery revascularization | BSX Boston Scientific Corporation | — | Not yet recruiting | 60 | Sep 30, 2027 | Registry ↗ |
| Oct 30, 2026 | Combined CM and STN Stimulation for Motor Epilepsy NCT07458217 · Motor Epilepsy Deep brain stimulation | BSX Boston Scientific Corporation | Not applicable | Recruiting was not yet recruiting | 10 | May 31, 2028 | Registry ↗ |
| Oct 30, 2026 | Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device NCT06192758 · Prostate, Cancer TheraSphere PCa | BSX Boston Scientific Corporation | Not applicable | Active, not recruiting | 36 | Jan 2028 | Registry ↗ |
| Oct 30, 2026 | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients… NCT05303467 · Glioblastoma Multiforme, Recurrent Glioblastoma TheraSphere GBM | BSX Boston Scientific Corporation | Phase 1 | Recruiting | 36 | Jan 31, 2027 | Registry ↗ |
| Oct 30, 2026 | TheraSphere With Durvalumab and Tremelimumab for HCC NCT05063565 · Hepatocellular Carcinoma TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imf… | BSX Boston Scientific Corporation | Phase 2 | Active, not recruiting | 100 | Jun 2027 | Registry ↗ |
| Oct 28, 2026 | Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) NCT01385176 · Heart Failure, Congestive Heart Failure Implant of investigational device system, Titration during… | BSX Boston Scientific Corporation | Not applicable | Active, not recruiting | 118 | May 2014 | Registry ↗ |
| Oct 27, 2026 | OPTION-EMEA Clinical Trial NCT07349121 · Atrial Fibrillation (AF), Stroke Prevention in Patients Wit… Concomitant pulsed field ablation (PFA) and left atrial app… | BSX Boston Scientific Corporation | Not applicable | Recruiting | 500 | Dec 2028 | Registry ↗ |
| Oct 27, 2026 | OverStitch NXT Endoscopic Suture System NCT07276815 · Weight Loss OverStitch NXT Endoscopic Suture System | BSX Boston Scientific Corporation | Not applicable | Recruiting | 136 | Oct 31, 2028 | Registry ↗ |
| Oct 27, 2026 | Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365') NCT07195708 · Weight Loss Treatment group | BSX Boston Scientific Corporation | Not applicable | Recruiting | 144 | Jun 30, 2028 | Registry ↗ |
| Oct 27, 2026 | FARAPULSE™ Pulsed Field Ablation System NCT06762717 · Paroxysmal AF FARAPULSE™ Pulsed Field Ablation system | BSX Boston Scientific Corporation | — | Active, not recruiting | 501 | Dec 31, 2027 | Registry ↗ |
| Oct 27, 2026 | A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China NCT03736226 · Cardiovascular Diseases SYNERGYTM Stent System | BSX Boston Scientific Corporation | — | Active, not recruiting | 2,000 | Aug 1, 2024 | Registry ↗ |
| Oct 26, 2026 | PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II) NCT07106970 · Persistent Atrial Fibrillation Linear ablation, PVI alone | BSX Boston Scientific Corporation | Not applicable | Recruiting | 640 | Dec 30, 2027 | Registry ↗ |
| Oct 26, 2026 | A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embo… NCT06819865 · Acute Pulmonary Embolism EkoSonicTM Endovascular System | BSX Boston Scientific Corporation | — | Recruiting | 30 | May 30, 2028 | Registry ↗ |
| Oct 23, 2026 | A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With El… NCT07820930 · Atrial Fibrillation (AF), Persistent Atrial Fibrillation (P… FARAFLEX Mapping and Pulsed Field Ablation System | BSX Boston Scientific Corporation | Not applicable | Not yet recruiting | 650 | Jul 2029 | Registry ↗ |
| Oct 23, 2026 | Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrill… NCT07575269 · Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fib… FARAFLEX Mapping and Pulsed Field Ablation (PFA) System | BSX Boston Scientific Corporation | Not applicable | Recruiting | 571 | Jul 20, 2028 | Registry ↗ |
| Oct 23, 2026 | Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System NCT07444320 · Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillat… FARAPULSE™ Pulsed Field Ablation (PFA) System | BSX Boston Scientific Corporation | Not applicable | Recruiting | 200 | Feb 2028 | Registry ↗ |
| Oct 23, 2026 | A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wa… NCT07187115 · Atrial Fibrillation (AF), Persistant Atrial Fibrillation FARAPOINT Pulsed Field Ablation System, OptiMap System (non… | BSX Boston Scientific Corporation | Not applicable | Active, not recruiting | 699 | Jan 2027 | Registry ↗ |
| Oct 23, 2026 | A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NA… NCT06808217 · Atrial Fibrillation, Pulsed Field Ablation FARAPULSE Pulsed Field Ablation System | BSX Boston Scientific Corporation | — | Active, not recruiting | 550 | Apr 1, 2027 | Registry ↗ |
| Oct 23, 2026 | Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With… NCT06735534 · Persistent Atrial Fibrillation FARAPULSE™ Pulsed Field Ablation System | BSX Boston Scientific Corporation | Not applicable | Active, not recruiting | 376 | Apr 2027 | Registry ↗ |
| Oct 23, 2026 | FARAPULSE Workflow Assessment Registry NCT06656884 · Atrial Fibrillation (AF) | BSX Boston Scientific Corporation | — | Active, not recruiting | 524 | Feb 15, 2027 | Registry ↗ |
| Oct 23, 2026 | Feasibility Study of the FARAFLEX Mapping and PFA System NCT06510556 · Atrial Fibrillation, Persistent Atrial Fibrillation FARAFLEX Ablation Treatment, ELEVATE-COR Sub-study | BSX Boston Scientific Corporation | Not applicable | Recruiting | 250 | Feb 15, 2027 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:14 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances